Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

Table 3 Model variables: utilities

	Sensitivity analysis
	Base value	Minimum	Maximum	Distribution
Combination therapy
Stable disease	0.72	0.54	0.9	Binomial
Treatment complication	0.72	0.54	0.9	Binomial
Progression	0.59	0.4425	0.7375	Binomial
Progression with complication	0.59	0.4425	0.7375	Binomial
Death	0	0	0	Binomial
Monotherapy
Stable disease	0.73	0.5475	0.9125	Binomial
Treatment complication	0.73	0.5475	0.9125	Binomial
Progression	0.59	0.4425	0.7375	Binomial
Progression with complication	0.59	0.4425	0.7375	Binomial
Death	0	0	0	Binomial

ISSN: 1471-230X